Mutations in K-ras and Epidermal Growth Factor Receptor Expression in Korean Patients With Stages III and IV Colorectal Cancer

Abstract

K-Ras somatic mutations in advanced colorectal cancer (CRC) can predict resistance to mAbs that target the epidermal growth factor receptor (EGFR). The relationships between K-ras mutations and the EGFR status have not yet been examined, especially in Korean patients. A total of 82 colorectal tumors (stage III-IV) were analyzed. K-Ras mutations at codons 12 and 13 were detected by polymerase chain reaction—single strand conformational polymorphism. The EGFR expressions were examined by immunohistochemistry, and these were graded according to a modified EGFR expression scoring system. The relationships between the patients’ characteristics and the survival time and the gene mutation status were analyzed. The EGFR expression was positive in 69 patients (84.1%) and negative in 13 patients (15.9%). The K-ras mutation rate was 35.4%. In all, 20 (68.9%) cases were mutated at codon 12 and 9 (31.1%) cases were mutated at codon 13. No relationship was observed between the EGFR status and K-ras mutation. The median overall survival (OS) was 68.1 months. There was no difference between the K-ras mutant group and the wild type group for overall survival (30.3% vs 21.0%, respectively, at 36 months, P = .777). K-ras mutation and the EGFR status were not independent prognostic factors for OS (P = .105 and P = .499, respectively). For the Korean patients with CRC, the rate of an EGFR protein expression was greater than that for the patients in Western countries, and the rate of K-ras mutations was lower than that for patients in Western countries. This study found no correlation between the EGFR status and K-ras mutations in colorectal tumors.

Keywords

colon neoplasm epidermal growth factor receptor K-ras

Get full access to this article

View all access options for this article.

References

Goh KL , Quek KF , Yeo GT , et al. Colorectal cancer in Asians: a demographic and anatomic survey in Malaysian patients undergoing colonoscopy. Aliment Pharmacol Ther. 2005;22:859-864.

Kim DH , Ahn YO Molecular epidemiology of colon cancer. Cancer Res Treat. 2004;36:93-99.

Vogelstein B. , Fearon ER , Hamilton SR , et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-532.

Albitar M. , Yeh C. , Ma W. K-ras mutations and cetuximab in colorectal cancer. N Engl J Med. 2009;360:834.

Bengala C. , Bettelli S. , Bertolini F. et al. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol. 2009;20:469-474.

Dougherty U. , Sehdev A. , Cerda S. , et al. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin Cancer Res. 2008;14:2253-2262.

Kreeger PK , Mandhana R. , Alford SK , Haigis KM , Lauffenburger DA RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects. Cancer Res. 2009;69:8191-8199.

Lea IA , Jackson MA , Dunnick JK Genetic pathways to colorectal cancer. Mutat Res. 2009;670:96-98.

Ogino S. , Meyerhardt JA , Cantor M. , et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005;11:6650-6656.

10.

Nagahara H. , Mimori K. , Ohta M. , et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res. 2005;11:1368-1371.

11.

Schubbert S. , Shannon K. , Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7:295-308.

12.

Shaw P. , Tardy S. , Benito E. , Obrador A. , Costa J. Occurrence of Ki-ras and p53 mutations in primary colorectal tumors. Oncogene. 1991;6: 2121-2128.

13.

Greene FL , Balch CM , Fleming ID , et al, eds. AJCC Cancer Staging Manual. 6th ed. Chicago, IL: American Joint Committee on Cancer; 2002.

14.

Li AR , Chitale D. , Riely GJ , et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression . J Mol Diagn. 2008;10:242-248.

15.

Sholl LM , Xiao Y. , Joshi V. , et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry . Am J Clin Pathol. 2010;133:922-934.

16.

Cohen SJ , Cohen RB , Meropol NJ Targeting signal transduction pathways in colorectal cancer-more than skin deep. J Clin Oncol. 2005;23:5374-5385.

17.

Hilbe W. , Dlaska M. , Duba HC , et al. Automated real-time PCR to determine K-ras codon 12 mutations in non-small cell lung cancer: comparison with immunohistochemistry and clinicopathological features. Int J Oncol. 2003;23:1121-1126.

18.

Milano G. , Etienne-Grimaldi MC , Dahan L. , et al. Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer. Ann Oncol. 2008;19:2033-2038.

19.

Rego RL , Foster NR , Smyrk TC , et al. Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer. 2010;102:165-172.

20.

Karapetis CS , Khambata-Ford S. , Jonker DJ , et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.

21.

Yunxia Z. , Jun C. , Guanshan Z. , Yachao L. , Xueke Z. , Jin L. Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer. BMC Med Genet. 2010 ;11:34.

22.

Jeon CH , Lee HI , Shin IH , Park JW Genetic alterations of APC, K-ras, p53, MSI, and MAGE in Korean colorectal cancer patients. Int J Colorectal Dis. 2008 ;23:29-35.

23.

Breivik J. , Meling GI , Spurkland A. , Rognum TO , Gaudernack G. K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br J Cancer. 1994;69:367-371.

24.

Kislitsin D. , Lerner A. , Rennert G. , Lev Z. K-ras mutations in sporadic colorectal tumors in Israel: unusual high frequency of codon 13 mutations and evidence for nonhomogeneous representation of mutation subtypes. Dig Dis Sci. 2002;47:1073-1079.

25.

Bos JL , Fearon ER , Hamilton SR , et al. Prevalence of ras gene mutations in human colorectal cancers . Nature. 1987;327:293-297.

26.

Boughdady IS , Kinsella AR , Haboubi NY , Schofield PF K-ras gene mutations in adenomas and carcinomas of the colon. Surg Oncol. 1992;1:275-282.

27.

Fearon ER , Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.

28.

Bazan V. , Migliavacca M. , Zanna I. , et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol. 2002;13:1438-1446.

29.

Al-Mulla F. , Going JJ , Sowden ET , Winter A. , Pickford IR , Birnie GD Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol. 1998 ;185:130-138.

30.

Bell SM , Scott N. , Cross D. , et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology. 1993 ;104:57-64.

31.

Laurent-Puig P. , Olschwang S. , Delattre O. , et al. Association of Ki-ras mutation with differentiation and tumor-formation pathways in colorectal carcinoma. Int J Cancer. 1991;49:220-223.

32.

Lee JC , Wang ST , Lai MD , Lin YJ , Yang HB K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. Anticancer Res. 1996;16:3839-3844.

33.

Andersen SN , Lovig T. , Breivik J. , et al. K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol. 1997;32:62-69.

34.

Dix BR , Robbins P. , Soong R. , Jenner D. , House AK , Iacopetta BJ The common molecular genetic alterations in Dukes’ B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer. 1994;59:747-751.

35.

Hirvikoski P. , Auvinen A. , Servomaa K. , et al. K-ras and p53 mutations and overexpressions as prognostic factors in female rectal carcinoma. Anticancer Res. 1999;19:685-691.

36.

Samowitz WS , Curtin K. , Schaffer D. , Robertson M. , Leppert M. , Slattery ML Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev. 2000;9:1193-1197.